NCT00757523 - Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris | Biotech Hunter

Enrollment

382

Participants

Timeline

Start Date

September 10, 2008

Primary Completion Date

April 24, 2009

Study Completion Date

June 24, 2009

Conditions

Acne Vulgaris

Interventions

DRUG

Epiduo Gel

Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks

DRUG

Duac Gel

Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks

Trial Locations (17)

14052

GSK Investigational Site, Berlin

14169

GSK Investigational Site, Berlin

14469

GSK Investigational Site, Potsdam

20246

GSK Investigational Site, Hamburg

24148

GSK Investigational Site, Kiel

35392

GSK Investigational Site, Giessen

39120

GSK Investigational Site, Magdeburg

45122

GSK Investigational Site, Essen

48149

GSK Investigational Site, Münster

48249

GSK Investigational Site, Dülmen

53105

GSK Investigational Site, Bonn

60590

GSK Investigational Site, Frankfurt

76829

GSK Investigational Site, Landau

80337

GSK Investigational Site, München

80802

GSK Investigational Site, München

06847

GSK Investigational Site, Dessau

06097

GSK Investigational Site, Halle